Trials / Completed
CompletedNCT00001994
A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Glaxo Wellcome · Industry
- Sex
- All
- Age
- 13 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerance of atovaquone (566C80) in AIDS patients with central nervous system (CNS) toxoplasmosis. To evaluate the efficacy of 566C80 in the acute treatment and suppression of CNS toxoplasmosis in AIDS patients who fail or who cannot tolerate conventional therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atovaquone |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
22 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00001994. Inclusion in this directory is not an endorsement.